Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637899 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24548434 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL29637907 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24513568 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24513567 | 0.93 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL23679567 | 0.90 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL25382010 | 0.89 | KDM4E (0.63) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL26991473 | 0.88 | KDM4E (0.62) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL22315215 | 0.87 | KDM4E (0.74) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL9703289 | 0.87 | KDM4E (0.74) | KDM4ETAS1R3TAS1R1P2RY1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | KDM4E 4665/4885TAS1R3 4350/4885TAS1R1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.